Lacosamide

Description

Lacosamide · CAS 175481-36-4 · C13H18N2O3. UNII 563KS2PQY5. Boiling Point: 536.447; Melting Point: 140-146˚C; Solubility: 10-33.3 g/L.

Identification

CAS Registry Number	175481-36-4
PubChem CID	219078
Molecular formula	C13H18N2O3
IUPAC name	(2R)-2-acetamido-N-benzyl-3-methoxypropanamide
UNII (FDA)	563KS2PQY5

Computed Descriptors

Molecular Weight	250.29
XLogP3	0.3
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	3
Rotatable Bond Count	6
Exact Mass	250.13174244
Monoisotopic Mass	250.13174244
Topological Polar Surface Area	67.4
Heavy Atom Count	18
Formal Charge	0

Physical & Chemical Properties

Boiling Point	536.447
Melting Point	140-146˚C
Solubility	10-33.3 g/L
LogP	0.728

Physical description & handling notes

• Lacosamide is an antiepileptic drug with high oral potency, stereoselectivity, and anticonvulsant effects. By blocking sensory neuronal voltage-gated sodium channels that mediate neuropathic pain responses, lacosamide was shown to possess analgesic activity. Lacosamide is a chiral functionalized amino acid. The S-stereoisomer does not exhibit antiepileptic activity.

Regulatory Status

GHS notification summary	1.5% (1 / 66)

GHS Hazard Classification

GHS notification summary	1.5% (1 / 66)
Reported hazard statements	H301 (93.9%), H319 (93.9%)

Documented Uses

• Use (kg; approx.) in Germany (2009): >250
• Consumption (g per capita; approx.) in Germany (2009): 0.00305
• In the US and Europe, lacosamide is indicated for the treatment of partial-onset seizures in children and adults. In Canada, it is reserved for use in adults. It is also used as an adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients four years of age and older. The extended-release capsules of lacosamide are indicated for the treatment of partial-onset seizures in adults and in pediatric patients weighing at least 50 kg.
• Lacosamide is an amino acid derivative with a unique anticonvulsant activity that is used in combination with other agents as therapy of partial onset seizures. Lacosamide therapy is associated with a low rate of transient serum enzyme elevations and has been linked to rare instances of clinically apparent liver injury.
• Breast Feeding; Lactation; Milk, Human; Anticonvulsants
• Lacosamide (Class: Other Substances, Added Date: 06-2010)

Synonyms

Lacosamide; 175481-36-4; Erlosamide; Vimpat; Harkoseride; SPM 927; SPM-927; (r)-lacosamide 1; MOTPOLY; Lacosamida; DTXSID1057666; ADD 234037; 563KS2PQY5; SPM927; Propanamide, 2-(acetylamino)-3-methoxy-N-(phenylmethyl)-, (2R)-; ADD243037

Frequently Asked Questions

What are the CAS number and molecular formula of Lacosamide?

CAS 175481-36-4; molecular formula C13H18N2O3; molecular weight — g/mol.

What other names is Lacosamide known by?

Lacosamide, 175481-36-4, Erlosamide, Vimpat, Harkoseride, SPM 927.

Is Lacosamide classified as hazardous?

1.5% of GHS notifications report no hazard classification (1 of 66).

What are the key physical properties of Lacosamide?

Boiling Point: 536.447; Melting Point: 140-146˚C; Solubility: 10-33.3 g/L; LogP: 0.728.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.